Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ElutiaELUT +0.40%34 3-Year EPS without NRI Growth Rate is 32.20% as of Jun. 2026, which is 11% above its 10-year median of 28.90. GuruFocus rates ELUT with a GF Score™ of 34/100 and a GF Value™ of $0.76 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Elutia ranks better than 79% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 32.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 36.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Elutia was 42.90% per year. The lowest was -8.80% per year. And the median was 28.90% per year.
Elutia (NAS:ELUT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Elutia 3-Year EPS without NRI Growth Rate Related Terms
ELUT vs PAVM, NSPR, SNWV: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Elutia's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elutia 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Elutia's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Elutia's 3-Year EPS without NRI Growth Rate falls into.
Elutia 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 32.20% mean?
Elutia (ELUT) has a 3-Year EPS without NRI Growth Rate of 32.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Elutia and its competitors. This is 11% above median its historical median of 28.90. According to the industry distribution chart, Elutia ranks #139 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is Elutia's 3-Year EPS without NRI Growth Rate too high?
Elutia's current 3-Year EPS without NRI Growth Rate of 32.20% is 11% above median its 10-year median of 28.90. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Elutia's value of 32.20% is 300% above this industry median. Based on the distribution chart, Elutia ranks #139 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Elutia has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elutia's 3-Year EPS without NRI Growth Rate compare to PAVM and NSPR?
According to the Medical Devices & Instruments industry distribution chart, Elutia ranks #139 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Elutia in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Elutia's value of 32.20% is 300% above this benchmark. While the company's 10-year median is 28.90 vs. the industry median of 8.05, Elutia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elutia's current 3-Year EPS without NRI Growth Rate of 32.20% is 300% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Elutia and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elutia's current 3-Year EPS without NRI Growth Rate is 32.20%, which is 11% above median its own 10-year median of 28.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elutia stock overvalued right now?
Based on GuruFocus' analysis, Elutia (ELUT) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.76, compared to a current price of $0.85 — trading 12.3% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 32.20%, which is 11% above median its 10-year median of 28.90 and 300% above the Medical Devices & Instruments industry median of 8.05. Elutia's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Elutia (ELUT), the current 3-Year EPS without NRI Growth Rate is 32.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elutia (ELUT) Overvalued in 2026?
Based on GuruFocus' analysis, Elutia stock appears to be overvalued.
The current stock price of $0.85 is trading 12.3% above its estimated GF Value™ of $0.76.
GuruFocus considers Elutia to be Modestly Overvalued.
Key valuation signals for ELUT:
3-Year EPS without NRI Growth Rate: 32.20% (11% above median its 10-year median of 28.90)
GF Value™: $0.76 vs. price of $0.85 (12.3% above fair value)
Industry Position: 300% above the Medical Devices & Instruments median (#139 of 662)
No single metric tells the full story. See the ELUT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
34GF Score
Get the complete analysis for ELUT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELUT has been successfully added to your 
